Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival

Table 4 Univariateand multivariate analysis for prognostic factors on overall survival

Univariate analysis
	Hazard ratio	95% confidence interval	P value
Male gender	0.730	0.327-1.627	0.442
Age, years	1.035	1.001-1.069	0.039
History of TURBT	0.986	0.465-2.087	0.971
ECOG performance status	3.182	1.388-7.291	0.006
Comorbidities	2.264	0.929-5.513	0.072
Clinical T stage	1.565	1.010-2.421	0.045
Hydronephrosis	1.825	0.901-3.692	0.095
RT duration, days	1.016	0.991-1.041	0.196
Concurrent chemotherapy	0.587	0.271-1.268	0.175
Prescribed doses to bladder tumor bed, Gy	0.914	0.858-0.972	0.005
Prescribed doses to whole bladder, Gy	1.001	0.999-1.001	0.245
Complete response (CR)	0.155	0.066-0.358	<0.001
Multivariate analysis
Age	1.064	1.023-1.107	0.002
Performance status	2.840	1.133-7.119	0.026
Complete response (CR)	0.098	0.040-0.240	<0.001

ISSN: 1748-717X